References
- Asunción M, Calvo RM, San Millán JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. JCEM 2000;85:2434–8
- Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800
- Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: position statement from European Society of Endocrinology. EJE 2014;171:1–29
- Azziz R. Polycystic ovary syndrome: what's in a name? JCEM 2014;99:1142–5
- Yilmaz M, Isaoglu U, Delibas IB, Kadanali S. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res 2011;37:1020–6
- Ladrón de Guevara A, Fux-Otta C, Crisosto N, et al. Metabolic profile of the different phenotypes of polycystic ovary syndrome in two Latin American populations. Fertil Steril 2014;101:1732–9
- Hosseinpanah F, Barzin M, Keihani S, et al. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study. Clin Endocr (Oxf) 2014;81:93–9
- Podolski AJ, Brooks ED, Chizen DR, et al. Prevalence of polycystic ovary syndrome phenotypes using updated criteria for polycystic ovarian morphology: an assessment of over 100 consecutive women self-reporting features of polycystic ovary syndrome. Clark Reprod Sci 2014;21:1034–43
- Lin R, White JH. The pleiotropic actions of vitamin D. Bioessays 2004;26:21–8
- Muscogiuri G, Mitri J, Mathieu C, et al. Mechanisms in endocrinology: vitamin D as a potential contributor in endocrine health and disease. EJE 2014;171:R101–10
- Wolden-Kirk H, Gysemans C, Verstuyf A, Mathieu C. Extraskeletal effects of vitamin D. Endocrinol Metab Clin North Am 2012;41:571–94
- Lai YH, Fang TC. The pleiotropic effect of vitamin D. ISRN Nephrol 2013;2013:898125. doi: 10.5402/2013/898125
- Pitas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D response element in the human insulin receptor gene promoter. JCEM 2007;92:2017–19
- Maestro B, Molero S, Bajo S, et al. Transcriptional activation of the human insulin receptor gene by 1,25-hydroxyvitamin D. Cell Biochem Funct 2002;20:227–32
- Wortsman J, Matsouka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690–3
- Kim JJ, Choi YM, Chae SJ, et al. Vitamin D deficiency in women with polycystic ovary syndrome. Clin Reprod Med 2014;41:80–5
- Yildizhan R, Kurdoglu M, Adali E, et al. Serum 25 hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet 2009;280:559–63
- Mahmoudi T, Gourabi H, Ashrafi M, et al. Calcitropic hormones, insulin resistance and the polycystic syndrome. Fertil Steril 2010;93:1208–14
- Hahn S, Haselhorst U, Tan S, et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2006;114:577–83
- Lerchbaum E, Obermayer-Pietsch B. Vitamin D and fertility: a systematic review. Eur J Endocrinol 2012;166:765–78
- Wehr E, Trummer O, Giuliani A, et al. Vitamin D-receptor gene polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. EJE 2011;164:741–5
- Mahmoudi T. Genetic variation in the vitamin D receptor and polycystic ovary syndrome risk. Fertil Steril 2009;92:1381–3
- Bagheri M, Rad IA, Jazani NH, Nanbakhsh F. Lack of association of vitamin D receptor FokI (rs10735810) (C/T) and BsmI (rs1544410) (A/G) genetic variations with polycystic ovary syndrome risk: a case control study from Iranian Azeri Turkish women. Maedica (Buchar) 2012;7:3033–308
- Bagheri M, Rad A, Hosseini JN, Nanbakhsh F. Vitamin D receptor TaqI gene variant in exon 9 and polycystic ovary syndrome risk. Int J Fertil Steril 2013;7:116–21
- El-Shal AS, Shalaby SM, Aly NM, et al. Genetic variation in the vitamin D receptor gene and vitamin D serum levels in Egyptian women with polycystic ovary syndrome. Mol Biol Reprod 2013;40:6063–73
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Fertil Steril 2004;81:19–25
- Lenarcik-Kabza A, Łaczmanski Ł, Milewicz A, et al. The influence of endocannabinoid receptor 1 gene variations on anthropometric and metabolic parameters of women with polycystic ovary syndrome. Endokrynol Pol 2014;65:181–8
- Laczmanski L, Milewicz A, Puzianowska-Kuznicka M, et al. Interrelation between genotypes of the vitamin D receptor gene and serum sex hormone concentrations in the Polish elderly population: the PolSenior study. Exp Gerontol 2014;57:188–90
- Lwow F, Dunajska K, Milewicz A, et al. Effect of moderate-intensity exercise on oxidative stress indices in metabolically healthy obese and metabolically unhealthy obese phenotypes in postmenopausal women: a pilot study. Menopause 2011;18:646–53
- Gallea M, Granazotto M, Azzolini S, et al. Insulin and body weight but not hyperandrogenism seem involved in seasonal serum 25-OH-vitamin D3 levels in subjects affected by PCOS. Gynecol Endocrinol 2014;13:1–7
- Hernandez JL, Olmos JM, Romana G, et al. Influence of vitamin D status on the effect of statins on bone mineral density and bone turnover markers in postmenopausal women. J Clin Endocrinol Metab 2014;99:3304–9